Navigation Links
Catalyst Pharmaceutical Partners Selected to Present at Epilepsy Conference Highlighting New and Promising Therapies
Date:2/17/2010

logical side effects profile," said Steven Miller, Ph.D., Catalyst's Chief Scientific Officer.  "CPP-115 was designed specifically to enhance the deactivation of GABA aminotransferase compared to Sabril®.  This enhanced action is expected to lead to significantly higher potency and may lead to reduced, or eliminated, visual field defects.  Sabril's® visual field defects are its most serious side effect and the main reason that the drug is sold only through a very restrictive Risk Evaluation and Mitigation Strategy (REMS) program.  We are hopeful that CPP-115 will prove to be an effective anti-epileptic with a more favorable safety and efficacy profile than Sabril®."

The conference features leading innovators, clinical investigators and industry leaders who provide insight into the discovery and development of pioneering drugs, biologics and devices for epilepsy with the goal of accelerating patient access to new treatments. The selected presenters are scheduled to discuss the most innovative therapies in development for epilepsy.  For additional program information, please visit www.epilepsy.com/node/985708.  

About CPP-115

CPP-115 is Catalyst's lead compound for the treatment of epilepsy and addiction being developed as part of an exclusive worldwide license between Northwestern University and Catalyst. CPP-115 is covered by two composition of matter patents related to a new class of GABA aminotransferase inhibitors. CPP-115 allows Catalyst to potentially explore a broad range of CNS applications, starting with epilepsy, which could benefit from the inhibition of GABA aminotransferase.


'/>"/>
SOURCE Catalyst Pharmaceutical Partners, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. IDEXX Laboratories Announces Catalyst Dx(R) Placement Total for 2009 and Installed Base of SmartService(TM) Customers
2. Catalyst Pharmaceutical Partners Reports Third Quarter 2009 Financial Results
3. Catalyst Pharmaceutical Partners, Inc. Announces Organizational Changes and Extension of Chief Executives Employment Agreement
4. Catalyst Pharmaceutical Partners, Inc. Announces the Closing of $3.97 Million Registered Direct Offering
5. Sigma-Aldrich(R) Partners With Flow Chemistry Leader ThalesNano to Provide CatCart(R) Catalyst Products for Rapidly Growing Market
6. Catalyst Pharmaceutical Partners, Inc. To Raise $3.97 Million In Registered Direct Offering
7. Catalyst Pharmaceutical Partners Continues Clinical Development of CPP-109 For The Treatment of Cocaine and Methamphetamine Addiction
8. Catalyst Pharmaceutical Partners Announces Top-Line Results of CPP-109 Phase II Trial for Cocaine Addiction
9. Catalyst Reaches Enrollment Target for its U.S. Phase II Cocaine Trial
10. Catalyst Pharmaceutical Partners Announces Publication of Animal Data Demonstrating Vigabatrin Effective for Weight Loss
11. Catalyst Pharmaceutical Partners, Inc. Begins Enrollment for U.S. Phase II Clinical Trial of CPP-109 in Patients with Methamphetamine Addiction
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... Report Details  New ... companies  What does the future hold for ... Visiongain,s brand new report shows you potential revenues to ... Our 242-page report provides 185 tables, charts, and ... and the future market prospects. Our new study lets ...
(Date:3/27/2015)... 2015 The International Myeloma Foundation (IMF) – ... working toward prevention and a cure – today commended ... federal resolution (H. Res. 174) that supports the designation ... Myeloma Awareness Month." Currently there are more ... than 110,000 new cases are diagnosed yearly, according to ...
(Date:3/27/2015)... 27, 2015 RnRMarketResearch.com adds ... market research report of 52 pages with latest ... intelligence library. The report "Visceral Pain - Pipeline ... therapeutic development for Visceral Pain, complete with comparative ... target, mechanism of action (MoA), route of administration ...
Breaking Medicine Technology:Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2015-2025 2Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2015-2025 3Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2015-2025 4Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2015-2025 5Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2015-2025 6Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2015-2025 7The International Myeloma Foundation (IMF) Secures the Introduction of a Federal Resolution Recognizing March 2015 as "National Multiple Myeloma Awareness Month" 2Visceral Pain Pipeline Review H1 2015 Market Research Report 2Visceral Pain Pipeline Review H1 2015 Market Research Report 3Visceral Pain Pipeline Review H1 2015 Market Research Report 4
... MEETING, Pa., Feb. 10 Genaera Corporation (Nasdaq: ... clinical data for trodusquemine (MSI-1436), the first-in-class, highly selective ... the treatment of type 2 diabetes and obesity. ... data from the first of three cohorts in an ...
... A new study published today claiming that multivitamin ... risk of mortality fails to take into account important ... health claims are regulated by the U.S. Food and ... published in the February 9 issue of Archives ...
Cached Medicine Technology:Genaera Presents Preliminary Phase 1b Data for Trodusquemine (MSI-1436) 2Genaera Presents Preliminary Phase 1b Data for Trodusquemine (MSI-1436) 3Evidence Lacking in Multivitamin Study of Women's Risk of Cancer, Heart Disease or Death, Says Natural Products Association 2
(Date:3/27/2015)... New York, New York (PRWEB) March 27, 2015 ... lawsuits ( http://www.lipitorlawsuitcenter.com/ ) that allege the statin medication ... 2 diabetes has granted Pfizer Inc.’s Motion to Dismiss ... proceeding. According to a Case Management Order issued in ... March 23rd, the Court determined that the dismissals were ...
(Date:3/27/2015)... Healthpointe is proud to announce that ... now treating knee and hip joint disorders in practice ... Beach, and La Mirada. Dr. Stanley Katz specializes in ... joint disorders as well as chronic conditions such as ... his patients back to their normal lives. Many ...
(Date:3/27/2015)... (PRWEB) March 27, 2015 While deep learning ... 2015 GPU technology conference (GTC) , the CEO of one ... and push the human lifespan well beyond the generally-agreed ceiling ... informatics company , is one of 12 companies recognized as ... other startups in the GTC Emerging Companies Summit ...
(Date:3/27/2015)... On March 19, 2015, at ... Lions wide receiver Herman Moore, hosted “Fighting Addiction ... substance abuse, treatment options and the recent changes ... pastors, ministers and bishops from local churches as ... , “Our ‘Fighting Addiction Together’ luncheon was informative ...
(Date:3/27/2015)... FL and London, UK (PRWEB) March 27, 2015 ... announced today that it has appointed Sean Fitzgerald, a ... role of Chief Operating Officer and Interim Chief Financial ... President of leading education technology innovator, EverFi, backed by ... Schmidt, and Twitter founder Evan Williams. Prior to EverFi, ...
Breaking Medicine News(10 mins):Health News:Lipitor Lawsuits Move Forward in Federal Multidistrict Litigation, as Court Rules on Pfizer’s Motion to Dismiss Certain Cases 2Health News:Lipitor Lawsuits Move Forward in Federal Multidistrict Litigation, as Court Rules on Pfizer’s Motion to Dismiss Certain Cases 3Health News:Fellowship-Trained and Board-Certified Orthopedic Surgeon is Now Treating Knee and Hip Joint Disorders in Anaheim, California 2Health News:Fellowship-Trained and Board-Certified Orthopedic Surgeon is Now Treating Knee and Hip Joint Disorders in Anaheim, California 3Health News:InSilico Medicine, Inc. Stands Out from High Tech Startups at 2015 GPU Conference 2Health News:InSilico Medicine, Inc. Stands Out from High Tech Startups at 2015 GPU Conference 3Health News:LiveToBeSober.org Hosts Conference on Substance Abuse Treatment and Recovery at Ford Field 2Health News:GenSight Appoints Former Technology Executive as Chief Operating Officer 2
... the University of Arkansas, Worcester Polytechnic Institute //and other ... to examine the fossils of our ancestors’ teeth to ... and why. ,By comparing teeth from two species ... researchers confirm previous evidence that A. africanus ate more ...
... has replaced the smoking pot and cigar of the 70s. ... 21st-century style, just stay on your cell phone and check ... ,A study commissioned by Hewlett-Packard shows that today's dependency ... slightly more detrimental to your IQ than smoking marijuana. Conducted ...
... advocated in menopausal woman. However taking this hormone treatment ... recently anxiety has been expressed. ,In a study ... a cancer developing in woman on HRT is low and ... team from New South Wales Breast Cancer Institute looked at ...
... couples who smoke according to a new study// which has ... than cigarette-smoking women with non-smoking spouses. ,The study recorded ... stroke and ischemic stroke (a stroke caused by a blood ... of women. The relative risk of total stroke was 5.7 ...
... in the latest issue of BMJ said that multivitamins ... elderly population. ,At least 10% of older people ... to poor immunity and increased risk of infection. At ... take nutritional supplements, but it is unclear whether they ...
... choice by many for latest and quick medical treatment .A ... India for treatment after discovering he would have to wait ... The decision to seek treatment in India has been taken ... more than four months for an appointment after being left ...
Cached Medicine News:Health News:Scientists Develop New Technology To Find About Human Ancestors’ Teet 2Health News:E-Mail Affects Brain More Than Marijuana 2Health News:Risk of Breast Cancer Overestimated with Hormone Replacement Therapy(HRT) Treatment 2Health News:Indian Hospitals – A Destination For Quality Medical Care 2
... (IGF-I or somatomedin C) is a 7.6 kDa ... as a potent mitogen of cellular proliferation, exerting ... In the circulation, IGF-I is bound to IGF-binding ... of IGF-I by modulating the interaction of IGF-I ...
... name from its first known site of ... of PSA circulates bound to anti-chymotrypsin (PSA-ACT) ... PSA are elevated in patients with prostate ... [1-3]. In addition, PSA serum levels appear ...
Inquire...
The design of this table top is based on advanced functionality for specific urological requirements. This composite product sets a new standard for urological imaging....
Medicine Products: